Short-course paromomycin treatment of visceral leishmaniasis in India: 14-Day vs 21-day treatment

Clinical Infectious Diseases

Volumn 49, Issue 6, 2009, Pages 914-918

  Sundar, Shyam ^a   Agrawal, Neha ^a   Arora, Rakesh ^a   Agarwal, Dipti ^a   Rai, Madhukar ^a   Chakravarty, Jaya ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PAROMOMYCIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INDIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDIA; INJECTIONS, INTRAMUSCULAR; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PAROMOMYCIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70049103388     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605438     Document Type: Article

References (11)

1. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-1746 (Pubitemid 35375612)
2. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356:2571-2581 (Pubitemid 46961002)
3. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemie visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993;168:715-720 (Pubitemid 23254293)
4. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Lowdose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002;66:143-146 (Pubitemid 34755644)
5. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31:1110-1113 (Pubitemid 32299377)
6. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990;84:221-5.
7. Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992;86:615-616 (Pubitemid 23012903)
8. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007;77:89-94. (Pubitemid 351844356)
9. Sundar S, Rai M., Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47: 1000-1006
10. Clinical Trials.gov-National Institutes of Health. Clinical trials registry. Available at: http://www.clinicaltrials.gov/ct2/search. Accessed 12 January 2009.
11. World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases. Research to support the elimination of visceral leishmaniasis. TDR Business Line 10. Available at: http://www.who.int/ tdr/svc/publications/about-tdr/annual -reports/visceral-leishmaniasis- elimination-2008. Accessed 12 January 2009.